Unresectable Pancreatic Ductal Adenocarcinoma
8
3
5
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (8)
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma